Christopher Rex

Founder at Afraxis, Inc.

48 year

Consumer Services

Health Technology

Finance

Profile

Christopher Rex is the founder of Afraxis, Inc. which was founded in 2010, where he holds the title of Chief Scientific Officer.
He was also a Program Director at T123 LLC from 2018 to 2021.
Dr. Rex received his doctorate from the University of California, Irvine in 2008 and his undergraduate degree from the University of California, Santa Barbara in 2002.

Christopher Rex active positions

Companies	Position	Start
Afraxis, Inc. Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA.	Founder	31/12/2009

All active positions of Christopher Rex

Former positions of Christopher Rex

Companies	Position	End
T123 LLC T123 LLC Investment ManagersFinance I2020 Accelerator (I2020 Accelerator) is a venture capital firm founded in 2018. The firm is headquartered in San Diego, California.	Director/Board Member	31/03/2021

See the detail of Christopher Rex's experience

Training of Christopher Rex

University of California, Irvine	Doctorate Degree
University of California, Santa Barbara	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Christopher Rex's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Afraxis, Inc. Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA.	Health Technology
T123 LLC T123 LLC Investment ManagersFinance I2020 Accelerator (I2020 Accelerator) is a venture capital firm founded in 2018. The firm is headquartered in San Diego, California.	Finance